Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men : an open-label randomised substudy of the ANRS IPERGAY trial

2018

Article référencé dans le Web of Science WOS:000425938000038

Molina J. M., Charreau I., Chidiac C., Pialoux G., Cua E., Delaugerre C., Capitant C., Rojas-Castro D., Fonsart J., Bercot B., Bebear C., Cotte L., Robineau O., Raffi F., Charbonneau P., Aslan A., Chas J., Niedbalski L., Spire B., Sagaon Teyssier Luis, Carette D., Le Mestre S., Dore V., Meyer L., ANRS Ipergay Study Group

Lancet Infectious Diseases, 2018, 18 (3), p. 308-317 ISSN 1473-3099

Background Increased rates of sexually transmitted infections (STIs) have been reported among men who have sex with men. We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of STIs. Methods All participants attending their scheduled visit in the open-label extension of the ANRS IPERGAY trial in France (men aged 18 years or older having condomless sex with men and using pre-exposure prophylaxis for HIV with tenofovir disoproxil fumarate plus emtricitabine) were eligible for inclusion in this open-label randomised study. Participants were randomly assigned (1:1) at a central site to take a single oral dose of 200 mg doxycycline PEP within 24 h after sex or no prophylaxis. The primary endpoint was the occurrence of a first STI (gonorrhoea, chlamydia, or syphilis) during the 10-month follow-up. The cumulative probability of occurrence of the primary endpoint was estimated in each group with the Kaplan-Meier method and compared with the log-rank test. The primary efficacy analysis was done on the intention-to-treat population, comprising all randomised participants. All participants received risk-reduction counselling and condoms, and were tested regularly for HIV. This trial is registered with ClinicalTrials.gov number, NCT01473472. Findings Between July 20, 2015, and Jan 21, 2016, we randomly assigned 232 participants (n=116 in the doxycycline PEP group and n=116 in the no-PEP group) who were followed up for a median of 8.7 months (IQR 7.8-9.7). Participants in the PEP group used a median of 680 mg doxycycline per month (IQR 280-1450). 73 participants presented with a new STI during follow-up, 28 in the PEP group (9-month probability 22%, 95% CI 15-32) and 45 in the no-PEP group (42%, 33-53; log-rank test p=0.007). The occurrence of a first STI in participants taking PEP was lower than in those not taking PEP (hazard ratio [HR] 0.53; 95% CI 0.33-0.85; p=0.008). Similar results were observed for the occurrence of a first episode of chlamydia (HR 0.30; 95% CI 0.13-0.70; p=0.006) and of syphilis (0.27; 0.07-0.98; p=0.047); for a first episode of gonorrhoea the results did not differ significantly (HR 0.83; 0.47-1.47; p=0.52). No HIV seroconversion was observed, and 72 (71%) of all 102 STIs were asymptomatic. Rates of serious adverse events were similar in the two study groups. Gastrointestinal adverse events were reported in 62 (53%) participants in the PEP group and 47 (41%) in the no-PEP group (p=0.05). Interpretation Doxycycline PEP reduced the occurrence of a first episode of bacterial STI in high-risk men who have sex with men.

Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052] ; Santé : aspects socioculturels, économiques et politiques [056]

FRANCE

Fonds IRD [F B010072423]

fdi:010072423